The U.S. Food and Drug Administration has granted approval to Empaveli as the primary treatment for C3 glomerulopathy .The drug has received approval for patients over 12 years and above who work to ...

The company's customer wins this year suggest more revenue expansion to come. In fact, C3.ai forecasts fiscal 2026 sales to ...

This has led to strong growth for the company, with C3.ai's revenue rising 25% year over year in fourth-quarter fiscal year 2025 (ending April 30). It also expects strong growth for FY 2026, with ...

McLaren did not waste any time in stamping its authority on the Hungarian Grand Prix weekend, but Ferrari also look in fine form. F1Technical's senior writer ...

We've waited quite some time for a reasonable choice of affordable small electric cars, and while they’re not exactly coming ...

Upgrade your portfolio! C3.ai is a strong buy with explosive growth, top-tier partnerships, and AI exposure at a discount.

The full-season announcement, made in collaboration with the FIA and Formula 1, includes softer selections at Zandvoort and ...

This approval offers a promising new targeted treatment for patients aged 12 and older with C3 glomerulopathy (C3G) and primary immune complex membranoproliferative glomerulonephritis (IC-MPGN), ...

For three days inside the Charleston Convention Center, fire, EMS, law enforcement and dispatchers from the tri-county ...

I've been writing about the LG C3 OLED TV since its release in 2023, and it has consistently been a best-seller, thanks to ...

Apellis Pharmaceuticals has made pipeline progress and strengthened its balance sheet. Click here to read an analysis of APLS ...